The activity against Ehrlich's ascites tumors of doxorubicin contained in self assembled, cell receptor targeted nanoparticle with simultaneous oral delivery of the green tea polyphenol epigallocatechin-3-gallate

Biomaterials

Volumn 34, Issue 12, 2013, Pages 3064-3076

  Ray, Lipika ^a   Kumar, Pradeep ^b   Gupta, Kailash C ^a,b  

^a CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

^b CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

Author keywords

Antitumor activity; Dextran; Doxorubicin; Ehrlich's ascites carcinoma (EAC); Hyaluronic acid

Indexed keywords

ANNEXINS; ANTI-TUMOR ACTIVITIES; ANTICANCER DRUG; BIODEGRADABLE NANOPARTICLE; CANCER CELLS; CANCER CHEMOTHERAPY; CELL RECEPTORS; CHROMATIN CONDENSATION; DOXORUBICIN; DRUG LOAD; EHRLICH'S ASCITES CARCINOMA (EAC); ENTRAPMENT EFFICIENCY; EPIGALLOCATECHIN-3-GALLATE; GREEN TEA POLYPHENOLS; HYALURONIC ACIDS; IN-VITRO; MITOCHONDRIAL MEMBRANE POTENTIAL; NEW DIMENSIONS; NON-TARGETED; ORAL DELIVERY; SELF-ASSEMBLED; SURVIVAL RATE; SURVIVAL TIME; TARGETED NANOPARTICLE; THERAPEUTIC EFFICACY; TUMOR VOLUMES;

ANIMALS; CELL DEATH; CELL MEMBRANES; CHEMOTHERAPY; DEXTRAN; DISEASES; DRUG DOSAGE; DRUG PRODUCTS; NANOPARTICLES; ORGANIC ACIDS; TOXICITY; TUMORS;

SYNTHESIS (CHEMICAL);

DEXTRAN; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; HYALURONIC ACID; LIPOCORTIN 5; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIODEGRADABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RELEASE; EHRLICH ASCITES TUMOR; ENCAPSULATION; IN VITRO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TEA; TUMOR VOLUME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, EHRLICH TUMOR; CATECHIN; DOXORUBICIN; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; SPECTROPHOTOMETRY, ULTRAVIOLET; TEA;

ANIMALIA; MUS;

EID: 84873430815     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.044     Document Type: Article

References (64)

1. Stutman O. Tumor development after 3-methylcholanthrene in immunologically deficient athymic-nude mice. Science 1974, 183:534-536.
2. van Pel A., Boon T. Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 1982, 79:4718-4722.
3. van der Bruggen P., Traversari C., Chomez P., Lurquin C., De Plaen E., Van den Eynde B., et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991, 254:1643-1647.
4. Willimsky G., Blankenstein T. Sporadic immunogenic tumors avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
5. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
6. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Engl J Med 2001, 344:783-792.
7. Hall M.D., Okabe M., Shen D.W., Liang X.J., Gottesman M.M. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol 2008, 48:495-535.
8. Stewart D.J., Dulberg C.S., Mikhael N.Z., Redmond M.D., Montpetit V.A., Goel R. Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 1997, 40:293-308.
9. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008, 6:1-18.
10. Nagai N., Ogata H. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration time curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother Pharmacol 1997, 40:11-18.
11. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002, 2:750-763.
12. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
13. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
14. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986, 46:6387-6392.
15. Zhang L., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007, 2:1268-1271.
16. Abbasi S., Paul A., Shao W., Prakash S. Cationic albumin nanoparticles for enhanced drug delivery to treat breast cancer: preparation and in vitro assessment. J Drug Deliv 2012, 10.1155/2012/686108.
17. Ryu J.H., Lee A., Chu J.U., Koo H., Ko C.Y., Kim H.S., et al. Early diagnosis of arthritis in mice with collagen-induced arthritis, using a fluorogenic matrix metalloproteinase 3-specific polymeric probe. Arthritis Rheum 2011, 63:3824-3832.
18. Valodkar M., Rathore P.S., Jadeja R.N., Thounaojam M., Devkar R.V., Thakore S. Cytotoxicity evaluation and antimicrobial studies of starch capped water soluble copper nanoparticles. J Hazard Mater 2012, 201-202:244-249.
19. Schädlich A., Caysa H., Mueller T., Tenambergen F., Rose C., Göpferich A., et al. Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano 2011, 5:8710-8720.
20. Carrillo-Conde B., Song E.H., Chavez-Santoscoy A., Phanse Y., Ramer-Tait A.E., Pohl N.L., et al. Mannose-functionalized " pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol Pharm 2011, 8:1877-1886.
21. Brambilla D., Nicolas J., Le Droumaguet B., Andrieux K., Marsaud V., Couraud P.O., et al. Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun 2010, 46:2602-2604.
22. Boca S.C., Potara M., Gabudean A.M., Juhem A., Baldeck P.L., Astilean S. Chitosan-coated triangular silver nanoparticles as a novel class of biocompatible, highly effective photothermal transducers for in vitro cancer cell therapy. Cancer Lett 2011, 311:131-140.
23. Choi K.Y., Min K.H., Na J.H., Choi K., Kim K., Park J.H., et al. Self-assembled hyaluronic acid nanoparticles as a potential drug carrier for cancer therapy: synthesis, characterization, and in vivo biodistribution. J Mater Chem 2009, 19:4102-4107.
24. Frasher J.R.E., Laurent T.C., Laurent U.B.G. Hyaluronan: its nature, distribution, functions and turnover. J Intern Med 1997, 242:27-33.
25. Chen W.Y.J., Abatangelo G. Functions of hyaluronan in wound repair. Wound Rep Regen 1999, 7:79-89.
26. Auzenne E., Ghosh S.C., Khodadadian M., Rivera B., Farquhar D., Price R.E., et al. Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia 2007, 9:479-486.
27. Peer D., Margalit R. Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 2004, 6:343-353.
28. Zöller M. CD44: physiological expression of distinct isoforms as evidence for organ-specific metastasis formation. J Mol Med 1995, 73:425-438.
29. Smadja-Joffe F., Legras S., Girard N., Li Y., Delpech B., Bloget F., et al. CD44 and hyaluronan binding by human myeloid cells. Leuk Lymphoma 1996, 21:407-420.
30. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996, 125:47-58.
31. Mott M.G. Anthracycline cardiotoxicity and its prevention. Ann NY Acad Sci 1997, 824:221-228.
32. Yang C.S., Wang Z.Y. Tea and cancer: a review. J Natl Cancer Inst 1993, 58:1038-1049.
33. Stoner G.D., Mukhtar H. Polyphenols as cancer chemopreventive agents. J Cell Biochem 1995, 22:169-180.
34. Katiyar S.K., Mukhtar H. Tea in chemoprevention of cancer: epidemiological and experimental studies. Int J Oncol 1996, 8:221-238.
35. Yang C.S., Chen L., Lee M.-J., Landau J.M. Effects of tea on carcinogenesis in animal models and humans. Adv Exp Med Biol 1996, 401:51-61.
36. Lorenz M., Urban J., Engelhardt U., Baumann G., Stangl K., Stangl V. Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol 2009, 104:100-110.
37. Serafini M., Ghiselli A., Ferro-Luzzi A. In vivo antioxidant effect of green and black tea in man. Eur J Clin Nutr 1996, 50:28-32.
38. Rafat H.S., Cillard J., Cillard P. Hydroxyl radical scavenging activity of flavonoids. Phytochemistry 1987, 26:2489-2491.
39. Thakur V.S., Gupta K., Gupta S. The chemopreventive and chemotherapeutic potentials of tea polyphenols. Curr Pharm Biotechnol 2012, 13:191-199.
40. Jeong Y.I., Kim S.T., Jin S.G., Ryu H.H., Jin Y.H., Jung T.Y., et al. Cisplatin-incorporated hyaluronic acid nanoparticles based on ion-complex formation. J Pharm Sci 2008, 97:1268-1276.
41. Goldie H., Walker M., Kelley L., Gaines J. Free tumor cell growth in the peritoneal cavity (ascites tumor) of mice bearing subcutaneous tumors. Cancer Res 1956, 16:553-558.
42. Mitra S., Gaura U., Ghosh P.C., Maitra A.N. Tumor targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Control Release 2001, 74:317-323.
43. Upadhyay K.K., Mishra A.K., Chuttani K., Kaul A., Schatz C., Le-Meins J.F., et al. The in vivo behavior and antitumor activity of doxorubicin-loaded poly(γ-benzyl L-glutamate)-block-hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. Nanomed Nanotechnol 2012, 8:71-80.
44. Shukla Y., Taneja P. Anticarcinogenic effect of black tea on pulmonary tumors in Swiss albino mice. Cancer Lett 2002, 176:137-141.
45. Evens A.M., Prachand S., Shi B., Paniaqua M., Gordon L.I., Gartenhaus R.B. Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent. Clin Cancer Res 2004, 10:1481-1491.
46. Davis S., Weissp M.J., Wong J.R., Lampidis T.J., Chen L.B. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 1985, 260:13844-13850.
47. Bae Y., Nishiyama N., Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem 2007, 18:1131-1139.
48. Ashwin A., Bhirde A.A., Patel V., Gavard J., Zhang G., Sousa A.A., et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3:307-316.
49. Ozaslan M., Karagoz I.D., Kilic I.H., Guldur M.E. Ehrlich ascites carcinoma. Afr J Biotechnol 2011, 10:2375-2378.
50. Shah C.B., Barnett S.M. Swelling behavior of hyaluronic acid gels. J Appl Polym Sci 1992, 45:293-298.
51. Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
52. Culty M., Nguyen H.A., Underhill C.B. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992, 116:1055-1062.
53. Knudsen W. Tumor-associated hyaluronan: providing an extracellular matrix that facilitates invasion. Am J Pathol 1996, 148:1721-1726.
54. Yeo T.K., Nagy J.A., Yeo K.T., Dvorak H.F., Toole B.P. Increased hyaluronan at sites of attachment to mesentery by CD44-positive mouse ovarian and breast tumor cells. Am J Pathol 1996, 148:1733-1740.
55. Upadhyay K.K., Bhatt A.N., Mishra A.K., Dwarakanath B.S., Jain S., Schatz C., et al. The intracellular drug delivery and anti tumor activity of doxorubicin loaded poly (γ-benzyl L-glutamate)-b-hyaluronan polymersomes. Biomaterials 2010, 31:2882-2892.
56. Dorr R.T. Antineoplastics, chemoprotectants and immunosuppressants. Handbook of clinical drug data 1998, 157-212. Appleton & Lange, Stamford, CT. P.O. Anderson, J.E. Knoben (Eds.).
57. Maeda H., Bharate G.Y., Daruwalla J. Polymeric drugs for efficient tumor targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009, 71:409-419.
58. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjug Chem 1992, 3:351-362.
59. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.
60. Dorai T., Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett 2004, 215:129-140.
61. Green D.R., Reed J.C. Mitochondria and apoptosis. Science 1998, 281:1309-1312.
62. Chen D., Wan S.B., Yang H., Yuan J., Chan T.H., Dou Q.P. EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 2011, 53:155-177.
63. Stearns M.E., Amatangelo M.D., Varma D., Sell C., Goodyear S.M. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies. Am J Pathol 2010, 177:3169-3179.
64. Sadzuka Y., Sugiyama T., Sonobe T. Efficacies of tea components on doxorubicin induced antitumor activity and reversal of multidrug resistance. Toxicol Lett 2000, 114:155-162.